Abstract 159P
Background
The impact of time on the efficacy of advanced distal gastric cancer (ADGC) remains unclear. At 3 years postoperatively, the efficacy of oncologic surgery for ADGC needs to be confirmed.
Methods
A total of 1256 patients with ADGC at two teaching institutions in China from April 2007 to December 2014 were enrolled. The general data of the two groups were matched using propensity scores. Restricted mean survival time (RMST) was used to compare survival.
Results
After matching, 461 patients each in the open distal gastrectomy (ODG) and laparoscopic distal gastrectomy (LDG) groups were analyzed. The 3- and 5-year overall survival (OS) and disease-free survival in ODG group were comparable to those in LDG group. RMST-stratified analysis showed that the 3-year RMST of ODG group was similar to that of LDG group (-1.38 years, P=0.163) in cT4a patients, whereas the 5-year RMST had significant differences between groups (-8.36 years, P=0.005). In further stratified analysis, when patients with cT4a and tumor was >5 cm, the 3-year RMST of ODG group was similar to that of LDG group (0.98 year, P=0.480); however, the 5-year RMST was significantly longer in ODG group (4.67 years, P=0.042). Multivariate regression analysis showed that ODG is a protective factor for 5-year OS in patients with cT4a and tumors >5 cm.
Conclusions
Beyond 3 years, ODG can improve the survival of patients with serous infiltration and tumors >5 cm by reducing the risk of recurrence. The present findings can serve as a reference for the preoperative selection of GC surgery options and the setting of follow-up time for clinical studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
325P - Clinical characteristics and outcomes of cancer patients with COVID-19 infection: A retrospective study in a single center in the Philippines
Presenter: Frances Victoria Que
Session: e-Poster Display Session
326P - Management of diffuse large B cell lymphomas in the COVID-19 era
Presenter: David Ng
Session: e-Poster Display Session
327P - COVID-19 in patients with oncohematologic diseases in Kazakhstan
Presenter: Zaure Dushimova
Session: e-Poster Display Session
328P - Impact of COVID-19 pandemic on 30 days colorectal cancer patients mortality undergoing emergency operation
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
329P - Radiotherapy palliative and COVID-19: Experience of radiotherapy oncology department of Cancer Center Tlemcen, Algeria
Presenter: Asma Mous
Session: e-Poster Display Session
330P - COVID and cancer: Choosing between hammer and anvil
Presenter: Ullas Batra
Session: e-Poster Display Session
331P - The clock stopped with COVID-19 but continued ticking for cancer patients
Presenter: Sasi Shanmugam Senga
Session: e-Poster Display Session
336P - Efficacy of methylcobalamin administered intravenously for chemotherapy-induced peripheral neuropathy (CIPN): A prospective crossover study
Presenter: Jun Chen
Session: e-Poster Display Session
337P - A prospective study about the quality of life and chemotherapy-induced peripheral neuropathy
Presenter: Wala Ben Kridis
Session: e-Poster Display Session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session